{"id":1463271,"date":"2024-12-24T07:09:26","date_gmt":"2024-12-24T09:09:26","guid":{"rendered":"https:\/\/teknomers.com\/fr\/astrazeneca-daiichi-sankyo-retirent-leur-demande-dapprobation-par-lue-pour-un-medicament-contre-le-cancer-du-poumon\/"},"modified":"2024-12-24T07:09:30","modified_gmt":"2024-12-24T09:09:30","slug":"astrazeneca-daiichi-sankyo-retirent-leur-demande-dapprobation-par-lue-pour-un-medicament-contre-le-cancer-du-poumon","status":"publish","type":"post","link":"https:\/\/teknomers.com\/fr\/astrazeneca-daiichi-sankyo-retirent-leur-demande-dapprobation-par-lue-pour-un-medicament-contre-le-cancer-du-poumon\/","title":{"rendered":"Astrazeneca\/Daiichi Sankyo retirent leur demande d&#8217;approbation par l&#8217;UE pour un m\u00e9dicament contre le cancer du poumon"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div>\n<p>  Par Najat Kantouar <\/p>\n<p>  Dow Jones&#8211;Les soci\u00e9t\u00e9s pharmaceutiques AstraZeneca et Daiichi Sankyo retirent volontairement leur demande d&#8217;autorisation de mise sur le march\u00e9 du m\u00e9dicament Dato-Dxd pour le traitement du cancer du poumon avanc\u00e9 dans l&#8217;Union europ\u00e9enne. <\/p>\n<p>  Astrazeneca a annonc\u00e9 mardi que cette d\u00e9cision faisait suite aux retours de l&#8217;Agence europ\u00e9enne des m\u00e9dicaments. Les deux soci\u00e9t\u00e9s ont continu\u00e9 \u00e0 travailler pour rendre Dato-DXd accessible aux patients atteints d&#8217;un cancer du poumon dans l&#8217;UE, indique le communiqu\u00e9. <!-- sh_cad_2 --><\/p>\n<p>  Contacter l&#8217;auteur : Unternehmer.de@dowjones.com <\/p>\n<p>  DJG\/DJN\/cln <\/p>\n<p>  (FIN) Fils de presse Dow Jones<\/p>\n<p>  24 d\u00e9cembre 2024 \u00e0 04h02 HE (09h02 GMT)<\/p>\n<\/div>\n<div id=\"\">\n<h2 class=\"headline headline--h4\">Produits \u00e0 effet de levier s\u00e9lectionn\u00e9s sur AstraZeneca<\/h2>\n<p>Avec les knock-outs, les investisseurs sp\u00e9culatifs peuvent participer de mani\u00e8re disproportionn\u00e9e aux mouvements de prix. S\u00e9lectionnez simplement le levier souhait\u00e9 et nous vous montrerons les produits ouverts adapt\u00e9s sur AstraZeneca.<\/p>\n<p class=\"font-color-red display-none\" id=\"lvgCustomHandleInfo\">L&#8217;effet de levier doit \u00eatre compris entre 2 et 20<\/p>\n<p><span class=\"ad-hint ad-hint--right display-block\">Publicit\u00e9<\/span><\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.finanzen.net\/nachricht\/aktien\/astrazeneca-daiichi-sankyo-ziehen-eu-zulassungsantrag-fuer-lungenkrebsmittel-zurueck-14113382\" rel=\"nofollow noopener\" target=\"_blank\">ttn-fr-28<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Par Najat Kantouar Dow Jones&#8211;Les soci\u00e9t\u00e9s pharmaceutiques AstraZeneca et Daiichi Sankyo retirent volontairement leur demande d&#8217;autorisation de mise sur le march\u00e9 du m\u00e9dicament Dato-Dxd pour le traitement du cancer du poumon avanc\u00e9 dans l&#8217;Union europ\u00e9enne. Astrazeneca a annonc\u00e9 mardi que cette d\u00e9cision faisait suite aux retours de l&#8217;Agence europ\u00e9enne des m\u00e9dicaments. Les deux soci\u00e9t\u00e9s ont [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1420882,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[74340,3982,841,12327,442,454,960,27487,164,23146,185,11807,120539],"class_list":["post-1463271","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance","tag-astrazenecadaiichi","tag-cancer","tag-contre","tag-dapprobation","tag-demande","tag-leur","tag-lue","tag-medicament","tag-par","tag-poumon","tag-pour","tag-retirent","tag-sankyo"],"_links":{"self":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/posts\/1463271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/comments?post=1463271"}],"version-history":[{"count":0,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/posts\/1463271\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/media\/1420882"}],"wp:attachment":[{"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/media?parent=1463271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/categories?post=1463271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/teknomers.com\/fr\/wp-json\/wp\/v2\/tags?post=1463271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}